▶ 調査レポート

自己免疫疾患診断の世界市場:疾患別(全身性自己免疫疾患、局所性自己免疫疾患)、診断別(免疫蛍光アッセイ(IFA)、酵素結合免疫吸着法(ELISA)、ウエスタンブロッティング、ドットブロット、ラインブロット、マルチプレックスイムノアッセイ、凝集法、二重免疫拡散法、向流免疫電気泳動法、その他)、地域別分析

• 英文タイトル:Global Autoimmune Disease Diagnostics Market - Segmented by Disease Type, Diagnosis, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。自己免疫疾患診断の世界市場:疾患別(全身性自己免疫疾患、局所性自己免疫疾患)、診断別(免疫蛍光アッセイ(IFA)、酵素結合免疫吸着法(ELISA)、ウエスタンブロッティング、ドットブロット、ラインブロット、マルチプレックスイムノアッセイ、凝集法、二重免疫拡散法、向流免疫電気泳動法、その他)、地域別分析 / Global Autoimmune Disease Diagnostics Market - Segmented by Disease Type, Diagnosis, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08047資料のイメージです。• レポートコード:B-MOR-08047
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、自己免疫疾患診断の世界市場について調べ、自己免疫疾患診断の世界規模、市場動向、市場環境、疾患別(全身性自己免疫疾患、局所性自己免疫疾患)分析、診断別(免疫蛍光アッセイ(IFA)、酵素結合免疫吸着法(ELISA)、ウエスタンブロッティング、ドットブロット、ラインブロット、マルチプレックスイムノアッセイ、凝集法、二重免疫拡散法、向流免疫電気泳動法、その他)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・自己免疫疾患診断の世界市場インサイト
・自己免疫疾患診断の世界市場環境
・自己免疫疾患診断の世界市場動向
・自己免疫疾患診断の世界市場規模
・自己免疫疾患診断の世界市場規模:疾患別(全身性自己免疫疾患、局所性自己免疫疾患)
・自己免疫疾患診断の世界市場規模:診断別(免疫蛍光アッセイ(IFA)、酵素結合免疫吸着法(ELISA)、ウエスタンブロッティング、ドットブロット、ラインブロット、マルチプレックスイムノアッセイ、凝集法、二重免疫拡散法、向流免疫電気泳動法、その他)
・自己免疫疾患診断の世界市場:地域別市場規模・分析
・自己免疫疾患診断の北米市場規模・予測
・自己免疫疾患診断のアメリカ市場規模・予測
・自己免疫疾患診断のヨーロッパ市場規模・予測
・自己免疫疾患診断のアジア市場規模・予測
・自己免疫疾患診断の日本市場規模・予測
・自己免疫疾患診断の中国市場規模・予測
・自己免疫疾患診断のインド市場規模・予測
・自己免疫疾患診断の韓国市場規模・予測
・関連企業情報・競争状況

The global autoimmune disease diagnostics market is expected to register a CAGR of 7.5% during the forecast period of 2018–2023.The key factors propelling the market include the growing public awareness of autoimmune disease, improving laboratory automation, partnerships with physicians and clinical laboratories, technological advancements, expansion in coverage allowed by the Patient Protection and Affordable Care Act.

Growing Public Awareness of Autoimmune Disease

The rising awareness of autoimmune diseases through programs of research, education, support, and advocacy is a key factor boosting the usage rates. It is imperative that the public is more aware of their own risk factors for developing autoimmune diseases so that, as symptoms occur, they can seek diagnosis and begin a treatment regimen. The United States has the highest incidence of autoimmune diseases with about 50 million patients. The American Autoimmune Related Diseases Association (AARDA) is dedicated to eradicate autoimmune diseases. The AARDA aims to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. Similarly, there are other organizations who are striving to improve the R&D funding, patient awareness, and provide other socio-economic benefits to the patients. The increase in awareness levels coupled with improving healthcare infrastructure and reimbursement coverage is expected to drive the market expansion over the forecast period. The other factors, such as improved laboratory automation, partnerships with physicians and clinical laboratories, technological advancements, and expansion in coverage allowed by the Patient Protection and Affordable Care Act are driving the autoimmune disease diagnostics market.

Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results

Diagnosis of autoimmune diseases is a time-consuming process. It involves procedures such as serum testing for diseases like rheumatoid arthritis, Addison’s disease, Hashimoto’s disease, and others. Testing protocols allow autoimmune disorders to be diagnosed in a highly efficient and cost-effective manner. However, the turnaround time for the test results is slow, owing to lesser automation techniques. It takes days to deliver all test results to the patients with the proper explanation of false positive results. For example, autoimmune lymph proliferative syndrome is an autoimmune disease with a turnaround time of up to 12 weeks. A single gene sequencing takes four weeks. Therefore, this slow turnaround time is hindering the global autoimmune disease diagnostics market. The other factor, such as high frequency of false positive result is also hindering the market.

United States to Lead the Market in North America

In 2017, the United States autoimmune disease diagnostics market held the largest market share in North America due to the increasing healthcare expenditure and increasing prevalence of autoimmune diseases in the region. In the United States, 16% of the population suffers from autoimmune diseases, 78% of whom are women.

Key Developments in the Market

• October 2017: The US Food and Drug Administration cleared Roche’s Cobas Cdiff Nucleic acid test.
• August 2017: BioMérieux, received SERVICE 800 award in an annual conference held in Minneapolis.
• August 2017: Thermo Fisher Scientific acquired Patheon.

Major Players: F. HOFFMANN-LA ROCHE, EUROIMMUN AG, INOVA DIAGNOSTICS, INC., SIEMENS HEALTHINEERS, INC., BIOMÉRIEUX, TRINITY BIOTECH, THERMO FISHER SCIENTIFIC, MYRIAD GENETICS, ABBOTT LABORATORIES, and BIO-RAD LABORATORIES, among others.

Reasons to Purchase the Report

• Follow the current and future autoimmune disease diagnostics market in the developed and emerging markets.
• Examining the various perspectives of the market with the help of Porter’s Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report

• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Growing Public Awareness of Autoimmune Disease
6.1.2 Improved Laboratory Automation
6.1.3 Partnerships with Physicians and Clinical Laboratories
6.1.4 Technological Advancements
6.1.5 Expansion in Coverage Allowed by Patient Protection and Affordable Care Act
6.2 Restraints
6.2.1 Slow Turnaround Time for Autoimmune Disease Diagnostic Test Results
6.2.2 High Frequency of False Positive Result
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Disease Type
7.1.1 Systemic Autoimmune Disease
7.1.1.1 Rheumatoid Arthritis
7.1.1.2 Psoriasis
7.1.1.3 Systemic Lupus Erythematosus (SLE)
7.1.1.4 Multiple Sclerosis
7.1.1.5 Others
7.1.2 Localized Autoimmune Disease
7.1.2.1 Inflammatory Bowel disease
7.1.2.2 Type 1 Diabetes
7.1.2.3 Thyroid
7.1.2.4 Others
7.2 By Diagnosis
7.2.1 Immunofluorescence assays (IFA)
7.2.2 Enzyme-linked Immunosorbent Assay (ELISA)
7.2.3 Western Blotting
7.2.4 Dot Blot
7.2.5 Line Blot
7.2.6 Multiplex Immunoassay
7.2.7 Agglutination
7.2.8 Double Immune Diffusion
7.2.9 Counter Immune-electrophoresis
7.2.10 Others
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia & New Zealand
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of the Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbott Laboratories
9.2 Biomérieux
9.3 Bio-rad Laboratories
9.4 Euroimmun AG
9.5 F. Hoffmann-la Roche
9.6 Inova Diagnostics, Inc.
9.7 Myriad Genetics
9.8 Siemens Healthineers, Inc.
9.9 Thermo Fisher Scientific
9.10 Trinity Biotech
*List not Exhaustive
10. Future of the Market
11. Disclaimer